An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Akili, Inc. (Nasdaq: AKLI) announced a conference call and webcast to discuss its Q4 2022 and full year 2022 financial results on March 7, 2023, at 4:30 p.m. ET. Investors can access the live audio on the company's website. Akili is focused on developing cognitive treatments through digital technologies that engage users via video game experiences, targeting cognitive impairment.
Positive
Akili is pioneering cognitive treatments through innovative technology.
The company has products validated through clinical trials.
Engaging video game experiences are utilized for treatment.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday, March 7, 2023 at 4:30 p.m. ET.
A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An archived version of the webcast will be available on the company’s website following the event.
To access the call, dial 877-407-8029 (toll-free) or 201-689-8029 (international) and reference “Akili Q4 2022 Earnings.” International toll-free numbers are available here.
About Akili
Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.